Preclinical Study Identifies Potential Immunochemotherapeutic Option for Pancreatic Cancer
the Cancer Therapy Advisor take:
In a preclinical study led by Paul B. Fisher, MPh, PhD, and Luni Emdad, MBBS, PhD, researchers from the VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) discovered a potentially safe and effective novel treatment for pancreatic cancer.
Using immunochemotherapy, which enlists the patient’s immune system to battle their cancer, researchers found that the delivery of [pIC]PEI into a pancreatic cancer cell can trigger cancerous cell death while leaving normal pancreatic cells intact. With an less than 6% overall 5-year survival rate, the need for improved pancreatic cancer treatment is clear.
The high rates of death after diagnosis are attributed to the difficulty in diagnosis the disease before it progresses and spreads to other organs within the body in addition to the disease’s established drug resistance.
Dr. Emdad noted that pancreatic cancer is among the top five leading causes of cancer death within the United States and that immunotherapy may be a key in establishing effective treatment. The research was published in the journal Cancer Research and the research is the first to link the proteins associated with programmed cell death as prime mediators in cancer-specific killing via [pIC]PEI.
Their research indicated that in vitro [pIC]PEI causes cell death in pancreatic cancer cells, and that, in vivo, [pIC]PEI also inhibited tumor growth via cell death. More preclinical studies are being scheduled in order to learn more about the effectiveness of [pIC]PEI and researchers hope to eventually translate their research to help patients with pancreatic cancer.
Researchers discovered a potentially safe and effective novel treatment for pancreatic cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC